Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ10101012-0,49
KB104310440,48
PKN60,4560,49-0,85
Msft408,75408,94-0,22
Nokia4,73954,744-0,90
IBM261,8262,6-0,18
Mercedes-Benz Group AG61,0461,06-1,88
PFE25,5525,56-0,04
19.02.2025 15:23:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.02.2025
Karyopharm Therap (NASDAQ Cons)
Závěr k 18.2.2025 Změna (%) Změna (USD) Objem obchodů (ks)
0,63 2,17 0,01 1 072 319
Premarket19.02.2025 15:15:09
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
0,6001 0,60 0,62 -4,75 -0,03 195 158
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.02.2025
Popis společnosti
Obecné informace
Název společnostiKaryopharm Therapeutics Inc
TickerKPTI
Kmenové akcie:Ordinary Shares
RICKPTI.O
ISIN-
Prioritní akcieConv. Pref. Shrs Series A
Prioritní akcieConv. Pref. Shrs Series B
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs Series A-3
Prioritní akcieConv. Pref. Shrs Series A-4
Prioritní akcieConv. Pref. Shrs Series B-1
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.09.2024
Počet zaměstnanců k 23.02.2024 325
Akcie v oběhu k 04.12.2024 126 190 744
MěnaUSD
Kontaktní informace
Ulice85 Wells Avenue, Second Floor
MěstoNEWTON
PSČ02459
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 176 580 600
Fax13026555049

Business Summary: Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Karyopharm Therapeutics Inc revenues increased 2% to $114.7M. Net loss decreased 55% to $45.6M. Revenues reflect Pharmaceutical segment increase of 8% to $38.8M. Lower net loss reflects Pharmaceutical segment loss decrease of 16% to $26.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.89 to -$0.38.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.02.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorRichard Paulson5703.05.202103.05.2021
Executive Vice President, Chief Financial Officer, TreasurerLori Macomber5303.01.202503.01.2025
Executive Vice President, Chief Commercial OfficerSohanya Cheng4108.06.2021
Executive Vice President, Chief Development OfficerStuart Poulton-27.07.202222.02.2022
Executive Vice President, Chief Medical OfficerReshma Rangwala44
Senior Vice President, General Counsel, SecretaryMichael Mano47
Senior Vice President - Investor Relations and Corporate CommunicationsBrendan Strong-09.12.202409.12.2024